Cumberland Partners Ltd Makes New Investment in Edwards Lifesciences Corporation $EW

Cumberland Partners Ltd acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the medical research company’s stock, valued at approximately $852,000.

Other hedge funds have also recently bought and sold shares of the company. JPL Wealth Management LLC acquired a new stake in Edwards Lifesciences during the third quarter worth approximately $25,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $28,000. Hantz Financial Services Inc. raised its position in shares of Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after buying an additional 164 shares in the last quarter. Dorato Capital Management acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $29,000. Finally, Rakuten Securities Inc. raised its position in shares of Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on EW shares. The Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. BTIG Research lifted their price target on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Mizuho set a $95.00 price target on shares of Edwards Lifesciences and gave the company an “outperform” rating in a research report on Monday, April 13th. Evercore reiterated an “outperform” rating and issued a $93.00 price target on shares of Edwards Lifesciences in a research report on Friday, April 24th. Finally, UBS Group reiterated a “neutral” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $95.65.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $85.93 on Friday. The company’s 50 day simple moving average is $81.42 and its 200 day simple moving average is $82.89. The stock has a market capitalization of $49.48 billion, a price-to-earnings ratio of 45.71, a price-to-earnings-growth ratio of 2.15 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period last year, the firm posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $83.01, for a total value of $84,587.19. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at $3,177,507.96. This trade represents a 24.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 106,684 shares of company stock valued at $8,811,739 over the last three months. 0.31% of the stock is owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.